2017
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients
Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D’Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Journal Of Experimental & Clinical Cancer Research 2017, 36: 63. PMID: 28482906, PMCID: PMC5422964, DOI: 10.1186/s13046-017-0536-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Ovarian EpithelialCell Line, TumorCell MovementCell ProliferationCell Transformation, NeoplasticCystadenocarcinoma, SerousDisease ProgressionDNA RepairDrug Resistance, NeoplasmFemaleForkhead Box Protein M1Gene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansKaplan-Meier EstimateMiddle AgedNeoplasm GradingNeoplasm MetastasisNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisProtein IsoformsRNA, Small InterferingConceptsForkhead box M1FOXM1 expressionEOC cell linesSerous EOCNormal controlsEOC subtypesCox proportional hazards analysisWorse disease-specific survivalEpithelial ovarian cancer patientsCell linesPlatinum-resistant casesSnap-frozen biopsiesDisease-specific survivalPlatinum-resistant diseaseAdvanced FIGO stageProportional hazards analysisProtein overexpressionClinic-pathological parametersOvarian cancer patientsRT-qPCRTransient siRNA transfectionPARP inhibitor olaparibFIGO stageSerous histologySpecific survival
2012
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer
Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A. Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer. International Scholarly Research Notices 2012, 2012: 245756. PMID: 22792477, PMCID: PMC3390037, DOI: 10.5402/2012/245756.Peer-Reviewed Original ResearchIndependent prognostic factorPrognostic factorsPrognostic significanceOvarian cancerSerum vascular endothelial growth factor (VEGF) levelsVascular endothelial growth factor levelsPresence of ascitesLymph node involvementResidual tumor sizeSubgroup of patientsGood prognostic markerGrowth factor levelsPotential prognostic significanceMEDLINE/PubMedSVEGF levelsFIGO stageNode involvementOverall survivalTumor sizeTumor gradeEligible studiesPatient outcomesPrognostic markerInclusion criteriaPrognostic variablesDemographics of uterine serous cancer (USC) patients: A single institutional experience.
de Leon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Demographics of uterine serous cancer (USC) patients: A single institutional experience. Journal Of Clinical Oncology 2012, 30: e15581-e15581. DOI: 10.1200/jco.2012.30.15_suppl.e15581.Peer-Reviewed Original ResearchPast medical historyUterine cancerUSC patientsSEER dataBreast cancerPrior historyLargest single-institution experienceCommon uterine cancerSerous cancer patientsSmall institutional seriesSingle institution experienceSingle institutional experienceForms of cancerOlder ptsPt ageDiabetic womenPostmenopausal womenFIGO stageInstitutional seriesOral contraceptivesMenopause statusCancer patientsDisease stageMedical historyEstrogen dependency